VIVIAN PERLMAN: Open Payments
NPI 1811045263 · SCOTTSDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,856 in 146 payments from 33 companies in 2025. Trend: 2023 $3,424 · 2024 $3,392 · 2025 $2,856
Food & beverage: $2,751Speaker / faculty: $106
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $312 |
| UCB, Inc. | 12 | $229 |
| Lilly USA, LLC | 10 | $224 |
| Eisai Inc. | 8 | $211 |
| Alexion Pharmaceuticals, Inc. | 6 | $184 |
| PFIZER INC. | 19 | $183 |
| Teva Pharmaceuticals USA, Inc. | 5 | $172 |
| MDD US Operations, LLC | 2 | $155 |
| Novartis Pharmaceuticals Corporation | 7 | $153 |
| Neurocrine BioSciences, Inc. | 6 | $117 |
Products named: Leqembi, ULTOMIRIS, QULIPTA, KESIMPTA, NURTEC ODT, KISUNLA, AUSTEDO XR, INGREZZA.
Industry payments across AZ — which companies pay providers there.
